{"id":11096,"date":"2018-08-02T08:01:47","date_gmt":"2018-08-02T12:01:47","guid":{"rendered":"https:\/\/medicarereport.org\/?p=11096"},"modified":"2018-08-02T08:01:47","modified_gmt":"2018-08-02T12:01:47","slug":"how-rival-opioid-makers-sought-to-cash-in-on-alarm-over-oxycontins-dangers","status":"publish","type":"post","link":"https:\/\/medicarereport.org\/?p=11096","title":{"rendered":"How Rival Opioid Makers Sought To Cash In On Alarm Over OxyContin\u2019s Dangers"},"content":{"rendered":"<p>(By Fred Schulte for Kaiser Health News)<\/p>\n<p>As Purdue Pharma faced mounting criticism over deaths linked to OxyContin, rival drugmakers saw a chance to boost sales by stepping up marketing of similarly dangerous painkillers, such as fentanyl, morphine and methadone, Purdue internal documents reveal. <a href=\"https:\/\/khn.org\/news\/how-rival-opioid-makers-sought-to-cash-in-on-alarm-over-oxycontins-dangers\/?utm_campaign=KHN%3A%20First%20Edition&amp;utm_source=hs_email&amp;utm_medium=email&amp;utm_content=64919857&amp;_hsenc=p2ANqtz-9U5HmuLQD-XirZmAeaRs3LCsfWrkCvl7yU7tKHcez1lPMe4AVKnDudny4fe9GF8ShDxkZ_vf9xem-aUMwNTAwwGWFiKw&amp;_hsmi=64919857\">Continue reading article here&#8230;<\/a><\/p>\n<p style=\"margin: 0px 0px 15px; padding: 0px; outline: 0px; border: 0px currentColor; color: #444444; text-transform: none; line-height: 1.6; text-indent: 0px; letter-spacing: normal; font-family: 'Open Sans', serif; font-size: 15px; font-style: normal; font-weight: 400; word-spacing: 0px; vertical-align: baseline; white-space: normal; orphans: 2; widows: 2; font-stretch: inherit; background-color: #ffffff; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-variant-numeric: inherit; font-variant-east-asian: inherit;\">Kaiser Health News is a nonprofit national health policy news service that is part of the nonpartisan Henry J. Kaiser Family Foundation.<\/p>\n<p style=\"margin: 0px 0px 15px; padding: 0px; outline: 0px; border: 0px currentColor; color: #444444; text-transform: none; line-height: 1.6; text-indent: 0px; letter-spacing: normal; font-family: 'Open Sans', serif; font-size: 15px; font-style: normal; font-weight: 400; word-spacing: 0px; vertical-align: baseline; white-space: normal; orphans: 2; widows: 2; font-stretch: inherit; background-color: #ffffff; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; font-variant-numeric: inherit; font-variant-east-asian: inherit;\"><a href=\"https:\/\/medicarereport.org\/wp-content\/uploads\/2015\/10\/khn-logo1.png\"><img loading=\"lazy\" decoding=\"async\" class=\"alignnone wp-image-899\" src=\"https:\/\/medicarereport.org\/wp-content\/uploads\/2015\/10\/khn-logo1-300x156.png\" sizes=\"auto, (max-width: 129px) 100vw, 129px\" srcset=\"https:\/\/medicarereport.org\/wp-content\/uploads\/2015\/10\/khn-logo1-300x156.png 300w, https:\/\/medicarereport.org\/wp-content\/uploads\/2015\/10\/khn-logo1-1024x533.png 1024w, https:\/\/medicarereport.org\/wp-content\/uploads\/2015\/10\/khn-logo1-390x205.png 390w, https:\/\/medicarereport.org\/wp-content\/uploads\/2015\/10\/khn-logo1.png 1600w\" alt=\"\" width=\"129\" height=\"67\" \/><\/a><\/p>\n<pre>Notice: The link provided above connects readers to the full content of the posted article. The URL (internet address) for this link is valid on the posted date; medicarereport.org cannot guarantee the duration of the link\u2019s validity. Also, the opinions expressed in these postings are the viewpoints of the original source and are not explicitly endorsed by AMAC, Inc.; the AMAC Foundation, Inc.; or medicarereport.org.<\/pre>\n","protected":false},"excerpt":{"rendered":"<p>(By Fred Schulte for Kaiser Health News) As Purdue Pharma faced mounting criticism over deaths linked to OxyContin, rival drugmakers<\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[17,15],"tags":[],"class_list":["post-11096","post","type-post","status-publish","format-standard","hentry","category-emerging-health-issues","category-part-dprescription-drugs"],"_links":{"self":[{"href":"https:\/\/medicarereport.org\/index.php?rest_route=\/wp\/v2\/posts\/11096","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/medicarereport.org\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/medicarereport.org\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/medicarereport.org\/index.php?rest_route=\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/medicarereport.org\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=11096"}],"version-history":[{"count":1,"href":"https:\/\/medicarereport.org\/index.php?rest_route=\/wp\/v2\/posts\/11096\/revisions"}],"predecessor-version":[{"id":11097,"href":"https:\/\/medicarereport.org\/index.php?rest_route=\/wp\/v2\/posts\/11096\/revisions\/11097"}],"wp:attachment":[{"href":"https:\/\/medicarereport.org\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=11096"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/medicarereport.org\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=11096"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/medicarereport.org\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=11096"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}